Denosumab effective in reducing skeletal-related events
Amgen of Thousand Oaks, Calif., the maker of denosumab (Prolia) announced at a global conference last month the results of 2 integrated analyses of head-to-head pivotal phase 3 trials comparing the drug to zoledronic acid (Zometa, Novartis Pharmaceuticals), the current standard of care in the prevention of skeletal-related events in patients with advanced malignancies involving bone.
Amgen of Thousand Oaks, Calif., the maker of denosumab (Prolia) announced at a global conference last month the results of 2 integrated analyses of head-to-head pivotal phase 3 trials comparing the drug to zoledronic acid (Zometa, Novartis Pharmaceuticals), the current standard of care in the prevention of skeletal-related events (SREs) in patients with advanced malignancies involving bone.
In the separate analyses, denosumab demonstrated a clinically meaningful, consistent, and robust treatment effect across tumor types in the reduction of SREs, and it also prevented clinically relevant increases in pain, in comparison with zoledronic acid.
The analyses were presented at the 35th European Society for Medical Oncology (ESMO) Congress held in Milan, Italy, in October.
“Denosumab is superior to zoledronic acid in preventing skeletal-related events in breast cancer, prostate cancer, and other solid tumors,” Allan Lipton, MD, professor of Medicine & Oncology at the M.S. Hershey Medical Center of Penn State University, told Formulary.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
